| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Diniconazole targets the enzyme lanosterol 14α-demethylase, a cytochrome P-450 enzyme involved in the biosynthesis of ergosterol, an essential component of fungal cell membranes. By inhibiting this enzyme, it disrupts ergosterol biosynthesis, leading to impaired cell membrane integrity and function, which results in fungal cell death.
|
|---|---|
| ln Vitro |
In vitro, diniconazole demonstrates potent fungicidal activity by inhibiting lanosterol 14α-demethylation catalyzed by a yeast cytochrome P-450. Its activity is assessed using standard mycelial growth inhibition assays or spore germination tests. The compound's efficacy is measured by determining the concentration required to inhibit fungal growth by 50% (EC50).
|
| ln Vivo |
In vivo, diniconazole is used as a systemic fungicide with curative and protective action. It is applied to crops to prevent and treat fungal infections. Its systemic properties allow it to be taken up by plants and transported within tissues. Its effectiveness against a wide range of fungal pathogens makes it a valuable tool in agriculture.
|
| Enzyme Assay |
The in vitro enzyme assay for diniconazole measures its ability to inhibit lanosterol 14α-demethylase activity. These cell-free assays use fungal microsomal preparations or purified enzyme and measure the conversion of lanosterol to ergosterol. The compound's inhibitory potency (IC50) is determined by measuring the reduction in enzyme activity.
|
| Cell Assay |
In vitro cellular assays for diniconazole assess its antifungal activity against fungal pathogens. These assays typically involve culturing the target fungus in the presence of various concentrations of diniconazole and measuring fungal growth inhibition. Endpoints include mycelial growth diameter or optical density. The minimum inhibitory concentration (MIC) or EC50 values are determined from these assays.
|
| Animal Protocol |
In vivo animal studies for diniconazole are primarily conducted for toxicological assessment rather than pharmacological efficacy, as it is a pesticide. These studies typically involve oral administration to rodents to determine acute and chronic toxicity. Its use is regulated as a pesticide, and it is not a pharmaceutical agent.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for diniconazole are not extensively detailed in the available literature. As a fungicide, its environmental fate and transport are studied in the context of agricultural use. It is not intended for systemic administration in animals or humans.
|
| Toxicity/Toxicokinetics |
Diniconazole is a conazole fungicide with a safety profile typical of triazole fungicides. It has low acute toxicity in mammals but may cause developmental and reproductive effects at high doses. Its use is regulated as a pesticide. It is a skin and eye irritant. Appropriate safety precautions should be taken when handling this compound.
|
| References | |
| Additional Infomation |
(1E)-1-(2,4-dichlorophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)pent-1-en-3-ol is a triazole compound with the structure 4,4-dimethyl-2-(1,2,4-triazol-1-yl)pent-1-en-3-ol substituted with a 2,4-dichlorophenyl group at the 1-position. It is a dichlorobenzene, an olefin compound, a secondary alcohol, and also a triazole compound.
Diniconazole (CAS 83657-24-3) is a conazole fungicide used to control a range of diseases including mildew, bunts, and smuts systemically with curative and protective action. It inhibits lanosterol 14α-demethylation, disrupting ergosterol biosynthesis. It has a molecular formula of C15H17Cl2N3O and a molecular weight of 326.22. It is a pesticide and is not a pharmaceutical agent. |
| Molecular Formula |
C15H17N3OCL2
|
|---|---|
| Molecular Weight |
326.22098
|
| Exact Mass |
325.074
|
| CAS # |
83657-24-3
|
| PubChem CID |
6436605
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
501.1±60.0 °C at 760 mmHg
|
| Melting Point |
134~156℃
|
| Flash Point |
256.8±32.9 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.592
|
| LogP |
4.23
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
21
|
| Complexity |
384
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(C)C(/C(=C\C1=C(C=C(C=C1)Cl)Cl)/N2C=NC=N2)O
|
| InChi Key |
FBOUIAKEJMZPQG-AWNIVKPZSA-N
|
| InChi Code |
InChI=1S/C15H17Cl2N3O/c1-15(2,3)14(21)13(20-9-18-8-19-20)6-10-4-5-11(16)7-12(10)17/h4-9,14,21H,1-3H3/b13-6+
|
| Chemical Name |
(E)-1-(2,4-dichlorophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)pent-1-en-3-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~306.54 mM)
H2O : ~0.67 mg/mL (~2.05 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.66 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0654 mL | 15.3271 mL | 30.6542 mL | |
| 5 mM | 0.6131 mL | 3.0654 mL | 6.1308 mL | |
| 10 mM | 0.3065 mL | 1.5327 mL | 3.0654 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
